148 related articles for article (PubMed ID: 18065924)
1. [The Grenelle of MR contrast agents?].
Clément O
J Radiol; 2007 Nov; 88(11 Pt 1):1663. PubMed ID: 18065924
[No Abstract] [Full Text] [Related]
2. Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update.
Kanal E; Broome DR; Martin DR; Thomsen HS
Radiology; 2008 Jan; 246(1):11-4. PubMed ID: 17855656
[No Abstract] [Full Text] [Related]
3. Nephrogenic systemic fibrosis in Japan: advisability of keeping the administered dose as low as possible.
Tsushima Y; Takahashi-Taketomi A; Endo K
Radiology; 2008 Jun; 247(3):915-6. PubMed ID: 18487548
[No Abstract] [Full Text] [Related]
4. Are patients with moderate renal failure at risk for developing nephrogenic systemic fibrosis?
Saab G; Abu-Alfa A
Radiology; 2007 Sep; 244(3):930-1; author reply 931-2. PubMed ID: 17709844
[No Abstract] [Full Text] [Related]
5. [Nephrotoxicity of contrast media in magnetic resonance tomography (MRI)].
Heuck A; Reiser M
Internist (Berl); 1997 Dec; 38(12):1234-5. PubMed ID: 9465330
[No Abstract] [Full Text] [Related]
6. Gadoteridol-induced anaphylaxis - not a class allergy.
Galera C; Pur Ozygit L; Cavigioli S; Bousquet PJ; Demoly P
Allergy; 2010 Jan; 65(1):132-4. PubMed ID: 19796195
[No Abstract] [Full Text] [Related]
7. [Artificial contrasting during magnetic resonance tomography].
Sergeev PV; Panov OV; Egorova SV; Bolotova EN; Shimanovskii NL; Akhadov TA; Sviridov NK
Vestn Rentgenol Radiol; 1997; (1):45-52. PubMed ID: 9133071
[No Abstract] [Full Text] [Related]
8. How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease?
Perazella MA
Clin J Am Soc Nephrol; 2008 May; 3(3):649-51. PubMed ID: 18385396
[No Abstract] [Full Text] [Related]
9. Severe adverse reactions with contrast agents for magnetic resonance: clinical experience in 30,000 MR examinations.
De Ridder F; De Maeseneer M; Stadnik T; Luypaert R; Osteaux M
JBR-BTR; 2001 Aug; 84(4):150-2. PubMed ID: 11688727
[TBL] [Abstract][Full Text] [Related]
10. [Nephrogenic systemic fibrosis as an adverse drug reaction of gadolinium-based contrast media for magnetic resonance imaging].
Giersig C
Radiologe; 2007 Sep; 47(9):794-9. PubMed ID: 17713753
[TBL] [Abstract][Full Text] [Related]
11. [Nephrogenic systemic fibrosis (NSF)--implications for radiology].
Michaely HJ; Thomsen HS; Reiser MF; Schoenberg SO
Radiologe; 2007 Sep; 47(9):785-93. PubMed ID: 17624507
[TBL] [Abstract][Full Text] [Related]
12. Type of MRI contrast, tissue gadolinium, and fibrosis.
Do C; Barnes JL; Tan C; Wagner B
Am J Physiol Renal Physiol; 2014 Oct; 307(7):F844-55. PubMed ID: 25100280
[TBL] [Abstract][Full Text] [Related]
13. Gadolinium-Induced Fibrosis.
Todd DJ; Kay J
Annu Rev Med; 2016; 67():273-91. PubMed ID: 26768242
[TBL] [Abstract][Full Text] [Related]
14. Safety of MR contrast media.
Olukotun AY
Radiology; 1994 May; 191(2):584-5. PubMed ID: 8153348
[No Abstract] [Full Text] [Related]
15. Nephrogenic systemic fibrosis: risk factors and incidence estimation.
Sadowski EA; Bennett LK; Chan MR; Wentland AL; Garrett AL; Garrett RW; Djamali A
Radiology; 2007 Apr; 243(1):148-57. PubMed ID: 17267695
[TBL] [Abstract][Full Text] [Related]
16. Considerations in the choice of contrast media for MR imaging.
Brasch RC; Bennett HF
Radiology; 1988 Mar; 166(3):897-9. PubMed ID: 3340795
[No Abstract] [Full Text] [Related]
17. Safety of magnetic resonance imaging contrast agents.
Shellock FG; Kanal E
J Magn Reson Imaging; 1999 Sep; 10(3):477-84. PubMed ID: 10508312
[TBL] [Abstract][Full Text] [Related]
18. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide.
Bruce R; Wentland AL; Haemel AK; Garrett RW; Sadowski DR; Djamali A; Sadowski EA
Invest Radiol; 2016 Nov; 51(11):701-705. PubMed ID: 26885631
[TBL] [Abstract][Full Text] [Related]
19. Imaging patients with kidney disease: how do we approach contrast-related toxicity?
Perazella MA; Reilly RF
Am J Med Sci; 2011 Mar; 341(3):215-21. PubMed ID: 21139495
[TBL] [Abstract][Full Text] [Related]
20. Incidence and severity of acute adverse reactions to four different gadolinium-based MR contrast agents.
Okigawa T; Utsunomiya D; Tajiri S; Okumura S; Sasao A; Wada H; Oda S; Arimura H; Hayashida E; Urata J; Yamashita Y
Magn Reson Med Sci; 2014; 13(1):1-6. PubMed ID: 24492735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
